MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Livongo Health, the leading consumer digital health company focused on improving care of chronic conditions, has unveiled two studies that demonstrate that a cellular enabled blood glucose device offering individualized recommendations and personalized coaching sessions improve glycemic control for people with diabetes. The studies were presented at the 76th Annual American Diabetes Association Scientific Sessions in New Orleans, La.
As part of its research, Livongo studied more than 10,000 individuals between October 2014 and March 2016. Results of the studies indicate that individuals using the Livongo for Diabetes program report improved and sustained blood glucose control with 0.7% reduction in HbA1c and sustained glycemic control with 33mg/dL reduction in average blood glucose values up to one year accompanied by a 15% average decrease in likelihood of a day with hypoglycemia (BG<80mg/dL). Further, reducing days with high or low blood glucose readings combined with improving overall control indicates people using Livongo are spending less frequent time at dangerous blood glucose levels.
For people living with diabetes, HbA1c is used to measure blood glucose control over the past three months. With Livongo for Diabetes, up-to-date HbA1c can be calculated from real-time blood glucose values providing patients and caregivers with more regular, actionable metrics.
“There is a growing interest around the world from employers, hospitals and health systems, and health plans on how to effectively empower people living with diabetes. For many years, different technologies have been explored to assess how individuals can better manage their condition while combating rising healthcare costs,” said Glen Tullman, CEO of Livongo Health. “These studies are significant because they demonstrate the clinical improvement in a measure that is universally agreed upon as a key factor in diabetes management.”
The studies were completed by Jenna Bollyky, MD and Jennifer Schneider, MD, MS of Livongo Health, with Janelle Downing, PhD from the University of California, San Francisco School of Public Health. Demographic characteristics including age, gender, diabetes type and insulin use were analyzed. The mean blood glucose was calculated from blood glucose checks on Livongo meters and HbA1c was estimated using a formula based on blood glucose values over 90 days.
Download Livongo Health’s full report, Cellular-Enabled Glucose Meters, Coaching, and Real-Time Data: A Winning Combination for Effective Diabetes Self-Management, by clicking here.
About Livongo Health
Livongo is the leading consumer digital health company that empowers people with chronic conditions to live a better life. Livongo has developed a completely new approach for diabetes management that combines the latest technology with coaching. For more information visit: www.livongo.com.
View and download Livongo’s latest images for media use at www.livongo.com/press.